Cystic Fibrosis Trust   Report issue

Foundation Phase 2 Phase 3
Founded: London United States (1964)

Organization Overview

First Clinical Trial
2000
NCT00271310
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cystic Fibrosis Trust

Active Ingredients

Drugs in Phase 3 Trials (1)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (5)

cysteamine (cystagon) (1 trial)

ivacaftor (Kalydeco) (1 trial)

pgm169/gl67a (1 trial)

rpl554 (1 trial)

tezacaftor (Trifakta) (1 trial)

Drugs in Other Trials (1)

fluticasone (cutivate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 7